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A B s T r A C T
Minimal change nephropathy (MCNs) and focal segmental 
glomerulosclerosis (fsGs) are the main causes of the 
idiopathic nephrotic syndrome. MCNs usually responds 
to steroids and the long-term prognosis is generally good. 
However, some patients require prolonged treatment with 
immunosuppressive agents. fsGs generally follows a less 
favourable course: patients do not always respond to steroids 
and may progress to end-stage renal disease. recurrence of 
fsGs after renal transplantation is frequently observed and 
may result in graft loss. 
recently, anecdotal case reports have described long-term 
resolution of nephrotic syndrome due to MCNs or 
fsGs after treatment with rituximab. We present four 
patients with nephrotic syndrome due to MCNs, fsGs or 
recurrence of fsGs after kidney transplantation, who were 
treated with rituximab with variable success. A review of 
the recent literature suggests that anti-Cd20 antibodies 
may be a promising therapy, especially for patients with 
MCNs or idiopathic fsGs. Controlled studies are required 
to determine the efficacy of rituximab and to define which 
patients will benefit.
K E Y W o r d s
Focal segmental glomerulosclerosis, minimal change 
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i N T r o d U C T i o N
Minimal change nephropathy (MCNS) and focal segmental 
glomerulosclerosis (FSGS) are the main causes of the 
idiopathic nephrotic syndrome. 
r E V i E W
rituximab in minimal change nephropathy 
and focal segmental glomerulosclerosis:  
report of four cases and review of the literature
H.P.E. Peters1*, N.C.A.J. van de Kar2, J.F.M. Wetzels1
Departments of 1Nephrology (464) and 2Paediatric Nephrology, Radboud University Nijmegen Medical 
Centre, Nijmegen, the Netherlands, *corresponding author: e-mail: H.Peters@aig.umcn.nl
MCNS is typically seen in children with a nephrotic 
syndrome. Patients with MCNS usually respond to treatment 
with prednisone. However, in 40 to 50% of all patients the 
disease runs a frequently relapsing course, often requiring 
additional immunosuppressive treatment with agents 
such as cyclophosphamide or cyclosporine. The long-term 
prognosis is generally good, but up to 25% of frequent 
relapsers may need prolonged treatment with two or more 
immunosuppressive agents.1 Cytokine release by T cells is 
supposed to play a key role in the pathogenesis of MCNS.2 
FSGS is considered less benign.3 Patients do not always 
respond to steroid treatment and may progress to end-stage 
renal disease. Relapse of focal segmental glomerulosclerosis 
after renal transplantation is observed in 30 to 50% of all 
patients. In most cases, proteinuria recurs within two to 
four weeks after renal transplantation. If untreated, graft 
loss will occur.4 FSGS is believed to be caused by a thus far 
unidentified circulatory permeability factor.5,6
Rituximab is a chimeric monoclonal antibody directed 
against the CD20 antigen which is present on B cells. 
Treatment with rituximab has been successful in patients 
with B cell lymphomas as well as in patients with 
autoimmune diseases, such as rheumatoid arthritis (RA), 
systemic lupus erythematosus (SLE) or immune complex 
glomerulonephritis such as membranous nephropathy.7-10 
Recently several case reports have suggested that rituximab 
may be effective in the treatment of patients with MCNS 
and FSGS. In this report we describe four patients with 
a nephrotic syndrome due to MCNS or FSGS who were 
treated with rituximab because of failure of or intolerance to 
the standard immunosuppressive therapy. The short-term 
outcome of two patients has previously been described.11,12 
We also provide a review of the literature concerning the 
treatment of MCNS and FSGS with rituximab.
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C A s E  r E P o r T s
Patient 1: MCNs
The medical history of this 20-year-old female patient and 
the short-term efficacy of rituximab has been described.12 
At the age of 2 years, she presented with nephrotic 
syndrome which responded to high-dose prednisone. 
However, the subsequent course was characterised by 
frequent relapses during childhood, despite treatment 
with various immunosuppressive therapeutic 
regimens consisting of prednisone, cyclophosphamide 
or cyclosporine. At the age of 18 years, the nephrotic 
syndrome was under control with the use of a low dose 
of prednisone (5 mg every other day) in combination with 
mycophenolate mofetil (MMF 1000 mg twice daily) and 
tacrolimus (target trough level 5 to 10 mg/l). Thereafter, the 
patient again developed relapses necessitating higher doses 
of prednisone. Ultimately remission could only be attained 
with very high doses of prednisone (60 mg/day). Heavy 
proteinuria (10 g/day) and low serum albumin (12 g/l) 
persisted while she was on prednisone (20 mg/day), MMF 
(1000 mg twice daily) and tacrolimus (15 mg twice daily, 
target trough level of 8-12 mg/l). This condition lasted more 
than a year and became intolerable. Therefore we decided 
to treat the patient with rituximab. She received two doses 
of 1000 mg intravenously with a two-week interval; MMF 
was stopped. Within two weeks there was a remarkable 
decrease in proteinuria (2 to 3 g/day) and an increase 
in serum albumin (21 g/l). Tacrolimus and prednisone 
were tapered and discontinued. Four months after the 
administration of rituximab, proteinuria was below 1 gram 
per day (figure 1). Return of CD20+ cells was observed after 
nine months. A relapse occurred 13 months after treatment 
with rituximab. Low-dose prednisone was not effective and 
the patient was again treated with rituximab (1000 mg, 
with a two-week interval). Administration of the first dose 
resulted in depletion of CD19+ and CD20+ B cells within 
two weeks. No adverse events occurred. However, during 
administration of the second dose of rituximab, she almost 
immediately developed hypotension, fever and dyspnoea. 
Antichimeric antibodies directed against rituximab proved 
positive. Despite B-cell depletion, heavy proteinuria (10 g/
day) and a low serum albumin (6 g/l) persisted. The patient 
is currently being treated with pulse methylprednisolone 
(3 g intravenously), tacrolimus (7 mg twice daily, target 
trough level 5 to 10 mg/l) and oral prednisone (10 mg/day). 
Serum albumin is 16 g/l and proteinuria 4 g/day. The 
clinical course is complicated by a recurring erysipelas.
Patient 2: fsGs
This male patient with FSGS was treated with rituximab 
at the age of 20 years. At the age of 12 years, he presented 
with a nephrotic syndrome due to biopsy-proven FSGS. 
Treatment with prednisone (60 mg/m2) was initiated. After 
several weeks, cyclosporine was added because of persisting 
proteinuria and prednisone was replaced by mycophenolate 
mofetil. One year after presentation, proteinuria was 1 
g/day and serum creatinine 90 µmol/l. At the age of 
16 years, the patient again developed nephrotic range 
proteinuria. Cyclosporine was replaced by tacrolimus, 
leading to a temporary decrease in proteinuria but a 
rise in serum creatinine (140 µmol/l). A renal biopsy, 
performed three years after starting tacrolimus, showed 
80% sclerosed glomeruli and moderate tubulointerstitial 
fibrosis. Tacrolimus was discontinued because of presumed 
toxicity and pulse methylprednisolone was administered 
(3 g intravenously) followed by oral prednisone (20 mg/day) 
with beneficial effects on proteinuria but not on serum 
creatinine. Renal function deteriorated and seven years 
after presentation serum creatinine was 170 µmol/l. At the 
age of 19 years, a relapse occurred during treatment with 
prednisone (10 mg/day) and mycophenolic acid (360 mg 
three times a day). Treatment with high doses of prednisone 
(60 mg/day) was initiated. This led to a complete remission, 
but during tapering of prednisone (to 25 mg/day) the 
patient experienced a relapse. We therefore decided to start 
treatment with anti-CD20 in this young male with high-dose 
steroid-responsive FSGS. Treatment consisted of two doses 
of rituximab (1000 mg intravenously) with a two-week 
interval. After the first dose of rituximab, mycophenolic 
acid was stopped and prednisone was continued in a dose of 
figure 1. Course in terms of proteinuria and serum 
albumin and response to treatment with rituximab in 
patient 1, %CD19/20+ B cells is given
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10 mg/day. Nephrotic range proteinuria persisted. Serum 
creatinine remained stable for six months but then renal 
function rapidly deteriorated necessitating renal replacement 
therapy. 
Patient 3: fsGs
This 15-year-old male was treated with rituximab because 
of relapsing nephrotic syndrome due to FSGS. The patient 
presented with a nephrotic syndrome at the age of 7 
years. A renal biopsy showed FSGS. Immunosuppressive 
treatment was started with cyclosporine and prednisone. 
Proteinuria gradually decreased and eventually a partial 
remission was attained. Three years after presentation a 
relapse occurred. Several courses of methylprednisolone 
(750 mg/day for three days) were given and mycophenolate 
mofetil was added to the immunosuppressive regimen. 
A partial remission was attained, but after six months a 
relapse occurred. High-dose prednisone therapy again 
led to a partial remission. Prednisone therapy was 
tapered and MMF was discontinued due to recurrent 
respiratory infections. Eventually cyclosporine was tapered 
and discontinued. At the age of 12, nephrotic range 
proteinuria recurred and the patient was treated with 
intravenous methylprednisolone, followed by prednisone 
and cyclophosphamide (2 to 3 mg/kg/day for 12 weeks). 
Partial remission was attained but tapering of prednisone 
to 25 mg every other day led to a rise in proteinuria. A renal 
biopsy performed six years after presentation showed 40% 
sclerosis of glomeruli and minor tubulointerstitial damage. 
Because of persisting proteinuria triple therapy was started 
at the age of 15. While on prednisone (tapered to 40 mg/
day), MMF (1000 mg twice daily) and tacrolimus (5 mg 
twice daily, target trough level 7 to 10 mg/l), the patient 
experienced a relapse. Treatment with rituximab was 
started (1000 mg intravenously at a two-week interval). No 
adverse events occurred. Approximately one month after 
receiving the first dose of rituximab, a profound decrease 
in proteinuria (2.11 g/l to 0.31 g/l) combined with an 
increased serum albumin (26 g/l to 34 g/l) was observed 
(figure 2). Six months after receiving rituximab, CD19 
and CD20 positive B cells were detected. Currently, ten 
months after the administration of rituximab, the patient 
has attained a complete remission while receiving minor 
doses of prednisone (3 mg every other day) and tacrolimus 
(2 mg twice daily).
Patient 4: recurrent fsGs after renal transplantation
The case report of this patient has been described by 
Deegens et al.11 At the age of 10, she presented with a 
nephrotic syndrome due to biopsy-proven FSGS. End-stage 
renal disease developed despite treatment with prednisone, 
cyclophosphamide and cyclosporine. At the age of 13 she 
received her first renal graft. Recurrence of FSGS led to 
graft failure after one year. Seven years later, she received 
a second renal graft. Baseline immunosuppressive therapy 
consisted of prednisone (10 mg), tacrolimus (target trough 
level 15 to 20 mg/l) and mycophenolate mofetil (750 mg 
twice daily). There was almost immediate graft function. 
One week after transplantation, the patient developed 
nephrotic range proteinuria. Because of a presumed 
recurrence of FSGS, plasma exchange (PE) was started 
which resulted in complete remission. Proteinuria 
recurred, however, three months after cessation of 
PE while the patient was on prednisone (15 mg) and 
tacrolimus (target trough level 5 to 10 mg/l). A second 
course of PE (eight sessions) again resulted in complete 
remission. A third relapse occurred two years later. A 
biopsy of the renal graft demonstrated diffuse foot process 
effacement, without significant lesions on light microscopy 
and immunofluorescence, supporting a diagnosis of 
recurrent FSGS. A remission of proteinuria could only 
be maintained with continuous PE, even though the 
patient was treated with a more intensive immunosup-
pressive regimen consisting of prednisone (10 mg), 
tacrolimus (target trough level 5 to 10 mg/l), and MMF 
(500 mg twice daily), which was replaced by azathioprine 
(2 mg/kg/day) because of gastrointestinal side effects. 
Given PE dependence, it was decided to start treatment 
with rituximab. Apart from a temporary neutropenia, 
no significant side effects occurred during the course 
of four weekly infusions (375 mg/m2). After treatment 
figure 2. Course in terms of proteinuria and serum 
albumin and response to treatment with rituximab in 
patient 3, %CD19/20+ B cells is given
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B-cell markers CD19+ and CD20+ were undetectable. 
Increasing proteinuria required three PE sessions during 
the first four months after treatment with rituximab. 
Thereafter, proteinuria gradually decreased without 
further interventions. Seven months after treatment with 
rituximab a partial remission (proteinuria <2 g/day) was 
attained. Nine months later, she experienced a relapse 
of proteinuria. At that time CD19+ and CD20+ B cells 
were still undetectable. The patient was again treated 
with a single infusion of rituximab 1000 mg. Proteinuria 
gradually decreased and a partial remission was reached 
two months after treatment
d i s C U s s i o N
We have described our experience with rituximab therapy 
in four patients with a nephrotic syndrome due to MCNS or 
FSGS. These cases suggest that rituximab may be effective 
in patients with nephrotic syndrome due to MCNS or FSGS. 
Admittedly, our data are anecdotal and controlled studies 
are required to prove the efficacy of rituximab. Nonetheless, 
we were impressed by the response in cases 1 and 3. 
These patients needed continuous treatment with various 
immunosuppressive agents for many years and ultimately 
remained severely nephrotic despite triple therapy with a 
calcineurin inhibitor, mycophenolate mofetil and prednisone. 
Following treatment with rituximab they developed a (nearly) 
complete remission while using no (case 1) or a limited 
dose (case 3) of immunosuppressive agents. In case 4, 
rituximab also appeared effective, although a response 
occurred slowly (after five months) and a contribution of 
plasmapheresis could not be excluded. The response to 
rituximab monotherapy after relapse, however, basically 
proved its efficacy. As illustrated by patient 2 and numerous 
case reports in the recent literature (tables 1 to 3), success 
varies. Furthermore, our cases illustrate a number of issues 
that may arise during treatment of nephrotic syndrome with 
rituximab, such as the relationship between proteinuria and 
circulating B cells and the potential development and role 
of antichimeric antibodies. We will discuss some of these 
issues briefly, after reviewing the literature on the treatment 
of nephrotic syndrome with rituximab. 
MCNs
Table 1 provides an overview of the use of rituximab in 
patients with MCNS.13-17 These reports have included both 
children and adults with a frequently relapsing nephrotic 
syndrome necessitating continuous immunosuppressive 
therapy. In all patients rituximab treatment resulted in a 
partial or complete remission of the nephrotic syndrome 
within two to ten weeks. In some patients concomitant 
immunosuppression could be stopped. In the study by 
Francois et al. remission was maintained while continuing 
intermittent administration of rituximab.14 Gilbert et 
al. successfully treated a relapse with a new course of 
rituximab.13 In contrast, our patient did not respond to 
a second course of rituximab after relapsing. Of note, in 
our patient treatment was not given according to protocol 
due to the development of antibodies causing serum 
sickness.
fsGs
The first case suggesting benefit from rituximab in 
FSGS was described in 2004. In this 16-year-old boy, 
the diagnosis of FSGS was made when he was 2 years 
of age and its clinical course was characterised by 
multiple relapses, despite treatment with steroids, 
cyclosporine, cyclophosphamide and tacrolimus. Finally, 
he became severely dependent on steroids. Subsequently, 
the diagnosis of idiopathic thrombocytopenic purpura 
(ITP) was made in this patient. Neither steroids nor 
immunoglobulins induced permanent remission and 
it was decided to treat the ITP with rituximab. After 
treatment with rituximab no relapse of proteinuria 
or thrombocytopenia occurred. Since then, several 
case reports have described the effect of rituximab in 
FSGS.16,18,19 So far, six patients (all children) with FSGS 
in their native kidney have been described, all of whom 
have been successfully treated (table 2). However, one 
must be aware of publication bias, since positive outcomes 
are more likely to be reported than negative ones. As 
illustrated by patient 3, treatment may fail. This could 
be due to the presence of irreversible damage before 
treatment with rituximab, considering the fact that renal 
biopsy showed 80% sclerosed glomeruli. Successful 
treatment with rituximab of a patient with FSGS and a 
diminished renal function has been described.19
recurrence of fsGs after transplantation
Thus far, 15 patients (including patient 4) with recurrent 
FSGS after transplantation who received rituximab have 
been described.20-28 An overview is given in table 3. 
These data suggest that response is variable and less 
favourable than in patients with MCNS or FSGS in their 
native kidneys. Moreover, interpretation of these data is 
difficult. In some patients who were treated successfully, 
rituximab was given to treat a coexisting posttransplant 
lymphoproliferative disorder (PTLD). It cannot be excluded 
that in these patients development of FSGS was related 
to the PTLD. In other patients rituximab was given in 
combination with plasmapheresis, making it impossible 
to draw conclusions on the efficacy of rituximab solely. 
On the other hand, response to rituximab may be slow as 
observed in patient 4, and consequently overlooked. Yabu 
et al. described a patient who did not respond within two 
months and received a short course of plasmapheresis. 
Thereafter proteinuria decreased from 6 to 1.9 g/day. In our 
Peters, et al. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis.
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Table 1. Rituximab in patients with minimal change nephropathy
Author sex Age at 
diagnosis
(years)
Age at 
start rTX 
(years)
rTX dose Concomitant 
therapy
response duration 
of follow-
up 
Comments
Gilbert F 1.5 15 375 mg/m2 
once weekly, 
4 doses
Deflazacort,
tacrolimus
Remission, 
not 
specified
18 months Relapse after 9 months. Response 
to steroids, relapse during 
tapering. After 16 months 
re infusion (2 weekly doses), again 
remission. Ongoing treatment 
with low dose of prednisone
Francois F 6 23 375 mg/m2 
once weekly, 
4 doses
Prednisone, 
basiliximab 
(stopped 
before 
rituximab)
CR within 
3 weeks
28 months One year after first dose, reinfu-
sion (2 weekly doses) because 
of detectable CD19/20 levels 
Persistent CR without immuno-
suppressive treatment
Smith M 3 13 375 mg/m2 
once 
Tacrolimus, 
MMF, 
prednisone
CR within 
2 weeks
6 months After 3 months return of 
CD19/20+ cells. Persistent CR, 
ongoing treatment with low doses 
of prednisone/ tacrolimus
Bagga NA
NA
1-3.3
1-3.3
2.8-16.0
2.8-16.0
375 mg/m2 
once weekly, 
4 doses
375 mg/m2 
once weekly, 
4 doses
CNI, 
prednisone 
CNI, 
prednisone
CR
CR or PR
14-58 
weeks
14-58 
weeks
Report of 5 patients with NS: 2 
MCNS, 3 FSGS
No differentiation between 
different patients possible. 
Ongoing treatment with pred-
nisone and tacrolimus/CsA
Yang F 40 40 375 mg/m2 
once weekly, 
4 doses
Prednisone, 
MMF
CR within 
10 weeks
12 months CR, ongoing treatment with low 
doses of prednisone and MMF
Present 
study
F 2 20 1 g every 
other week, 
2 doses
Prednisone, 
MMF, 
tacrolimus
PR within 
4 weeks
16 months PR for 12 months without immu-
nosuppressive treatment. Relapse 
after 13 months, retreatment with 
RTX not effective
Ns = nephrotic syndrome; MCNs = minimal change nephropathy; fsGs = focal segmental glomerulosclerosis; rTX = rituximab; CNi = calcineurin 
inhibitor; MMf = mycophenolate mofetil; CsA = cyclosporine; Cr = complete remission; Pr = partial remission; M = male; f = female; NA = not 
available.
Table 2. Rituximab in patients with focal segmental glomerulosclerosis
Author sex Age at 
diagnosis
(years)
Age at 
start rTX
(years)
rTX dose Concomitant 
therapy
response follow-up Comments
Benz M 2 16 375 mg/m2 
once weekly, 
4 doses
Prednisone, 
CsA
Remission, 
not 
specified
12 months Treated for ITP, no relapses on 
CsA monotherapy
Bagga NA
NA
NA
1-3.3
1-3.3
1-3.3
2.8-16.0 
2.8-16.0 
2.8-16.0 
375 mg/m2 
once weekly, 
4 doses
375 mg/m2 
once weekly, 
4 doses
375 mg/m2 
once weekly, 
4 doses
CNI, 
prednisone 
CNI, 
prednisone 
CNI, 
prednisone
CR
CR
CR or PR
14-58 
weeks
14-58 
weeks
14-58 
weeks
Report of 5 patients with NS: 2 
MCNS, 3 FSGS
No differentiation between 
different disease entities possible
Ongoing treatment with pred-
nisone and tacrolimus /CsA
Nakayama F
F
8
11
10
12
375 mg/m2 
once
375 mg/m2 
once
Prednisone
Prednisone, 
CsA
CR within 
8 months
PR within 
1 month
14 months
14 months
PR after 1, CR after 8 months, no 
immunosuppressive therapy
Relapse after 8 months. After 
second course of RTX PR within 2 
and CR within 5 months, ongoing 
treatment with prednisone
Present 
study
M
M
12
7
20
15
1 g every 
other week, 
2 doses
1 g every 
other week, 
2 doses
Prednisone, 
MMF
Prednisone, 
tacrolimus, 
MMF
None
CR within 
1 month
7 months
10 months 
80% of glomeruli showed 
sclerosis
CR with low doses of prednisone 
and tacrolimus
Ns = nephrotic syndrome; MCNs = minimal change nephropathy; fsGs = focal segmental glomerulosclerosis; iTP = idiopathic thrombocytopenic 
purpura; rTX = rituximab; CNi = calcineurin inhibitor; MMf = mycophenolate mofetil; CsA = cyclosporine; Cr = complete remission; Pr = partial 
remission; M = male; f = female; NA = not available.
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Table 3. Rituximab in patients with recurrent FSGS after transplantation
Author sex Age at 
rTX 
treatment 
(years)
rTX dose Concomitant 
therapy
Previous 
plasma 
exchange
response follow-up 
(months)
Comments
Pescovitz M 7 375 mg/m2 
once weekly, 
6 doses
Tacrolimus, 
MMF 
(daclizumab)
Yes, 
response?
PR within 
2 months
16 Treatment with rituximab 
because of PTLD
Nozu M 12 375 mg/m2 
once weekly, 
4 doses
CsA No CR within 
7 months
36 Treatment with rituximab 
because of PTLD
Gossman F 48 375 mg/m2 
once weekly, 
2 doses
Prednisone, 
tacrolimus, 
MMF, ATG
Yes, no 
response
CR within 
1.5 month
12 
El Firjani F 48 375 mg/m2 
6 doses in 8 
weeks
Prednisone, 
tacrolimus, 
MMF, ATG
Yes, no 
response
None NA
Hristea M 22 375 mg/m2 
once weekly, 
2 doses
Prednisone, 
tacrolimus, 
MMF, 
basiliximab
Yes, partial 
response
CR after 3 
months
24 PE and RTX were given 
concomitantly
Kamar M
M
25
46
375 mg/m2 
once weekly, 
2 doses
375 mg/m2 
once weekly, 
4 doses
Prednisone, 
CsA, MMF, 
basiliximab
Prednisone, 
CsA, MMF
Yes, pre-
emptive, 
partial 
response
Yes, no 
response
CR within 
1 week
None
10 
4 
PE and RTX were given 
concomitantly
A relapse (within 1 month!) was 
also treated with RTX and PE 
Proteinuria had already decreased 
before RTX was given
Marks M
M
6
10
375 mg/m2 
once weekly, 
4 doses
750 mg/m2 
every other 
week,  
2 doses
Prednisone, 
tacrolimus
Prednisone, 
tacrolimus, 
MMF
Yes, but 
incomplete 
due to 
infections 
Yes, partial 
response
None
None
5 
14 
No complete B-cell depletion
No complete B-cell depletion 
No remission but stable at once 
weekly PE
Meyer F 31 375 mg/m2 
once weekly, 
3 doses
Prednisone Yes, pre-
emptive 
partial 
response
PR 14 One weekly dose not given 
because of UTI, decrease of  
proteinuria 5 months after RTX
Yabu M
F
F
F
41
43
41
47
1 g every 
other week, 
2 doses
375 mg/m2 
once weekly, 
4 doses
375 mg/m2 
once weekly, 
4 doses
375 mg/m2 
once weekly, 
4 doses
Prednisone, 
tacrolimus, 
MMF
Prednisone, 
tacrolimus, 
MMF, ATG
Prednisone, 
MMF, CsA, 
ATG, total 
lymphoid 
irradiation
JAK3 
inhibitor, 
MMF, 
prednisone
Yes, partial 
response
Yes, partial 
response
Yes, no 
response
Yes, partial 
response
PR within 
4 months
None
None
None
12 
10 
7 
8 
Received PE 2 months after RTX
Dialysis after 7 months, transplant 
nephrectomy after 10 months
Stable serum creatinine  
(88 µmol/l) and serum albumin
Stable serum creatinine  
(140 µmol/l) and serum albumin
Present 
study
F 24 375 mg/m2 
once weekly, 
4 doses
Prednisone, 
tacrolimus, 
azathioprine
Yes, partial 
response
PR within 
7 months
24 Relapse after 16 months, after 
second course of RTX PR within 
2 months
PTld = posttransplant lymphoproliferative disorder; UTi = urinary tract infection; PE = plasma exchange; rTX = rituximab; CNi = calcineurin 
inhibitor; MMf = mycophenolate mofetil; CsA = cyclosporine; Cr = complete remission; Pr = partial remission; M = male; f = female; NA = not 
available.
opinion a positive effect of rituximab cannot be excluded 
in this patient. Of note, in two out of eight nonresponsive 
patients, complete B-cell depletion was not achieved. 
Lastly, successful treatment of patients with recurrence of 
FSGS and a severely diminished renal function has been 
reported.24, 25
Overall, our case studies and a review of the literature 
suggest that anti-CD20 therapy may expand the therapeutic 
arsenal for patients with MCNS or FSGS. Controlled trials 
are needed to determine the true value of such treatment 
and more information is needed in order to determine 
which patients are likely to benefit.
Peters, et al. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis.
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immunoregulatory effects of B cells
Since FSGS and MCNS are not antibody-mediated diseases, 
the success of rituximab may seem surprising. However, 
B cells play an important role as immunoregulatory 
cells by both antigen presentation and cytokine release. 
Their elimination could have dampening effects on other 
immune cells such as T lymphocytes, dendritic cells, 
or macrophages. This hypothesis is supported by an 
observed reduction in activated T cells and a decrease in 
T-cell derived cytokines in patients with SLE and RA after 
treatment with rituximab.29,30
B-cell depletion and response
Administration of rituximab results in B-cell depletion. 
It is tempting to speculate that rituximab therapy may be 
monitored by measuring B cells. The data of our patients and 
those reported previously argue against an unambiguous 
relationship. Some patients do not respond despite B-cell 
depletion, others show a lack of correlation between the 
return of B cells and time of relapse. Similar observations 
have been made in patients with systemic diseases such 
as vasculitis or SLE.9 From these studies it was suggested 
that measurement of circulating B cells does not accurately 
reflect the presence of B cells in other compartments, such 
as bone marrow, lymphoid tissue and organs. B cells residing 
in these nonperipheral compartments may be more resistant 
to depletion.31 The presence of these residual cells could 
contribute to the disease and lead to a failure to respond or a 
relapse in the absence of circulating B cells. This phenomenon 
was observed in patient 4; no B cells were detected at the 
time of relapse of FSGS. Evaluation of the regeneration 
pattern of the subclasses of B cells after rituximab may also 
be important. In patients with RA, naive B cells returned 
within 12 months after treatment with rituximab, but CD27+ 
memory cells remained absent for a longer period of time.32 
This could explain why some patients remain in remission 
despite the return of B cells as is illustrated by patient 1 and 
other case reports.15-19 Thus, monitoring of peripheral B cells 
cannot be used as an indication to repeat treatment with 
anti-CD20 antibodies, since the return of B cells does not 
appear to directly coincide with the return of disease activity. 
The decision to repeat treatment with rituximab should be 
based on clinical symptoms.
Kinetics of rituximab in proteinuria
In patients with non-Hodgkin’s lymphoma (NHL), return of 
B cells was observed after six months and after 12 months 
B-cell counts had normalised in the majority of patients. 
Similar observations have been made in patients with RA. 
Fervenza et al. suggested that pharmacokinetic parameters 
may be different in patients with proteinuria since part 
of the administered antibody may be lost with protein-
containing urine.7 Rituximab levels were significantly 
lower in patients with idiopathic membranous nephropathy 
when compared with patients with RA. Indeed, in patients 
with idiopathic membranous nephropathy return of B cells 
was observed after three months and normalisation of B 
cells was observed after six months. However, there was no 
correlation between rituximab levels and proteinuria. In 
another study in patients with nephrotic range proteinuria, 
B-cell counts remained subnormal for 12 months.8 Thus, it 
is premature to draw firm conclusions regarding the effect 
of proteinuria on rituximab pharmacokinetics. Moreover, 
the relationship between rituximab levels and B-cell 
depletion needs further study. 
development of antibodies against rituximab
Due to the relapsing course of many nephropathies, it is likely 
that many patients will need repeated courses of rituximab. 
As indicated by the case history of patient 1, frequent 
administration of rituximab may lead to the development 
of antibodies. Since rituximab is a chimeric mouse/human 
antibody, it is less immunogenic than mouse monoclonal 
antibodies. Still human antichimeric antibodies (HACA) 
can develop. The reported incidence of HACA development 
varies widely. In B-NHL patients, HACA have been found 
in only one of 166 patients treated in the pivotal study, and 
in four of the 90 patients treated in another study.33,34 In 
contrast, HACA were observed in six out of 14 tested patients 
with idiopathic membranous nephropathy and in 11 out of 
17 patients with SLE.7,35 The clinical significance of HACA 
is controversial. The presence of HACA could be expected to 
lead to a decreased response to rituximab due to accelerated 
clearance, and an increased incidence of serum sickness. 
Some studies showed a lower efficacy of rituximab in the 
presence of HACA.35,36 In several other studies, however, 
no correlation between HACA and clinical response or 
infusion reactions was observed.7,10,37 Of note, one patient 
with relapsed lymphoma was successfully treated with a 
second course of rituximab, despite the presence of HACA.38 
Our patient clearly shows that HACA can be problematic. 
Further studies should evaluate if the development of HACA 
can be suppressed by using concomitant immunosup-
pressive therapy at the time of administration of rituximab. 
In patients with RA, development of antibodies against 
infliximab is reduced by the use of methotrexate.39 New 
humanised versions of anti-CD20 antibodies may ameliorate 
the problem of antibody formation.
C o N C l U s i o N
Although anti-CD20 antibodies seem to offer a perspective 
for the treatment of patients with nephrotic syndrome due 
to MCNS or FSGS, positive results should be viewed with 
the necessary caution, since they may be overestimated due 
to publication bias. Controlled studies must be performed to 
prove the efficacy of rituximab, to evaluate its cost-effectiveness 
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and to determine which patients will benefit. In the meantime 
it is important to establish guidelines for the rescue treatment 
of patients with steroid-dependent nephrotic syndrome. A 
nationwide registry could aid in finding early answers to some 
of the above-mentioned questions. 
r E f E r E N C E s
1.  Kyrieleis HA, Levtchenko EN, Wetzels JF. Long-term outcome after 
cyclophosphamide treatment in children with steroid-dependent and 
frequently relapsing minimal change nephrotic syndrome. Am J Kidney 
Dis. 2007;49:592-7.
2.  Cunard R, Kelly CJ. T cells and minimal change disease. J Am Soc Nephrol. 
2002;13:1409-11.
3.  Deegens JK, Steenbergen EJ, Wetzels JF. Review on diagnosis and 
treatment of focal segmental glomerulosclerosis. Neth J Med. 
2008;66:3-12.
4.  Andresdottir MB, Ajubi N, Croockewit S, Assmann KJ, Hibrands LB, Wetzels 
JF. Recurrent focal glomerulosclerosis: natural course and treatment with 
plasma exchange. Nephrol Dial Transplant. 1999;14:2650-6.
5.  Sharma M, Sharma R, Reddy SR, McCarthy ET, Savin VJ. Proteinuria 
after injection of human focal segmental glomerulosclerosis factor. 
Transplantation. 2002;73:366-72.
6.  Sharma M, Sharma R, McCarthy ET, Savin VJ. “The FSGS factor:” 
enrichment and in vivo effect of activity from focal segmental glomerulo-
sclerosis plasma. J Am Soc Nephrol. 1999;10:552-61.
7.  Fervenza FC, Cosio FG, Erickson SB et al. Rituximab treatment of 
idiopathic membranous nephropathy. Kidney Int. 2008;73:117-25.
8.  Ruggenenti P, Chiurchiu C, Brusegan V, et al. Rituximab in idiopathic 
membranous nephropathy: a one-year prospective study. J Am Soc 
Nephrol. 2003;14:1851-7.
9.  Smith KG, Jones RB, Burns SM, Jayne DR. Long-term comparison 
of rituximab treatment for refractory systemic lupus erythematosus 
and vasculitis: Remission, relapse, and re-treatment. Arthritis Rheum. 
2006;54:2970-82.
10.  Cohen SB, Emery P, Greenwald MW, et al. Rituximab for rheumatoid 
arthritis refractory to anti-tumor necrosis factor therapy: Results of a 
multicenter, randomized, double-blind, placebo-controlled, phase III 
trial evaluating primary efficacy and safety at twenty-four weeks. Arthritis 
Rheum. 2006;54:2793-806.
11.  Deegens JKJ, Wetzels JFM. Rituximab for plasma exchange-dependent 
recurrent focal segmental glomerulosclerosis after renal transplantation. 
NDT Plus Advance Access, published online on January 14, 2008. Oxford 
University Press.
12.  Hofstra JM, Deegens JK, Wetzels JF. Rituximab: effective treatment for 
severe steroid-dependent minimal change nephrotic syndrome? Nephrol 
Dial Transplant. 2007;22:2100-2.
13.  Gilbert RD, Hulse E, Rigden S. Rituximab therapy for steroid-
dependent minimal change nephrotic syndrome. Pediatr Nephrol. 
2006;21:1698-700.
14.  Francois H, Daugas E, Bensman A, Ronco P. Unexpected efficacy of 
rituximab in multirelapsing minimal change nephrotic syndrome in the 
adult: first case report and pathophysiological considerations. Am J 
Kidney Dis. 2007;49:158-61.
15.  Smith GC. Is there a role for rituximab in the treatment of idiopathic 
childhood nephrotic syndrome? Pediatr Nephrol. 2007;22:893-8.
16.  Bagga A, Sinha A, Moudgil A. Rituximab in patients with the steroid-
resistant nephrotic syndrome. N Engl J Med. 2007;356:2751-2.
17.  Yang T, Nast CC, Vo A, Jordan SC. Rapid remission of steroid and 
mycophenolate mofetil (mmf) resistant minimal change nephrotic syndrome 
after rituximab therapy. Nephrol Dial Transplant. 2008;23:377-80.
18.  Benz K, Dotsch J, Rascher W, Stachel D. Change of the course of steroid-
dependent nephrotic syndrome after rituximab therapy. Pediatr Nephrol. 
2004;19:794-7.
19.  Nakayama M, Kamei K, Nozu K, et al. Rituximab for refractory focal 
segmental glomerulosclerosis. Pediatr Nephrol. 2008;23:481-5.
20.  Pescovitz MD, Book BK, Sidner RA. Resolution of recurrent focal 
segmental glomerulosclerosis proteinuria after rituximab treatment. 
N Engl J Med. 2006;354:1961-3.
21.  Nozu K, Iijima K, Fujisawa M, Nakagawa A, Yoshikawa N, Matsuo M. 
Rituximab treatment for posttransplant lymphoproliferative disorder 
(PTLD) induces complete remission of recurrent nephrotic syndrome. 
Pediatr Nephrol. 2005;20:1660-3.
22.  Gossmann J, Scheuermann EH, Porubsky S, Kachel HG, Geiger H, Hauser 
IA. Abrogation of nephrotic proteinuria by rituximab treatment in a renal 
transplant patient with relapsed focal segmental glomerulosclerosis. 
Transpl Int. 2007;20:558-62.
23.  El-Firjani A, Hoar S, Karpinski J, Bell R, Deschenes MJ, Knoll GA. 
Post-transplant focal segmental glomerulosclerosis refractory 
to plasmapheresis and rituximab therapy. Nephrol Dial Transplant. 
2008;23(1):425.
24.  Hristea D, Hadaya K, Marangon N, et al. Successful treatment of recurrent 
focal segmental glomerulosclerosis after kidney transplantation by 
plasmapheresis and rituximab. Transpl Int. 2007;20(1):102-5.
25.  Kamar N, Faguer S, Esposito L, et al. Treatment of focal segmental 
glomerular sclerosis with rituximab: 2 case reports. Clin Nephrol. 
2007;67:250-4.
26.  Marks SD, McGraw M. Does rituximab treat recurrent focal segmental 
glomerulosclerosis post-renal transplantation? Pediatr Nephrol. 
2007;22:158-60.
27.  Meyer TN, Thaiss F, Stahl RA. Immunoadsorbtion and rituximab therapy 
in a second living-related kidney transplant patient with recurrent focal 
segmental glomerulosclerosis. Transpl Int. 2007;20:1066-71.
28.  Yabu JM, Ho B, Scandling JD, Vincenti F. Rituximab failed to improve 
nephrotic syndrome in renal transplant patients with recurrent focal 
segmental glomerulosclerosis. Am J Transplant. 2008;8:222-7.
29.  Sfikakis PP, Boletis JN, Lionaki S, et al. Remission of proliferative 
lupus nephritis following B cell depletion therapy is preceded by 
down-regulation of the T cell costimulatory molecule CD40 ligand: an 
open-label trial. Arthritis Rheum. 2005;52:501-13.
30.  Takemura S, Klimiuk PA, Braun A, Goronzy JJ, Weyand CM. T cell 
activation in rheumatoid synovium is B cell dependent. J Immunol. 
2001;167:4710-8.
31.  Gong Q, Ou Q, Ye S, et al. Importance of cellular icroenvironment and 
circulatory dynamics in B cell immunotherapy. J Immunol. 2005;174:817-26.
32.  Roll P, Palanichamy A, Kneitz C, Dorner T, Tony HP. Regeneration of B 
cell subsets after transient B cell depletion using anti-CD20 antibodies in 
rheumatoid arthritis. Arthritis Rheum. 2006;54(8):2377-86.
33.  McLaughlin P, Grillo-Lopez AJ, Link BK, et al. Rituximab chimeric 
anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma: 
half of patients respond to a four-dose treatment program. J Clin Oncol. 
1998;16:2825-33.
34.  Igarashi T, Kobayashi Y, Ogura M, et al. Factors affecting toxicity, response 
and progression-free survival in relapsed patients with indolent B-cell 
lymphoma and mantle cell lymphoma treated with rituximab: a Japanese 
phase II study. Ann Oncol. 2002;13:928-43.
35.  Looney RJ, Anolik JH, Campbell D, et al. B cell depletion as a novel 
treatment for systemic lupus erythematosus: a phase I/II dose-escalation 
trial of rituximab. Arthritis Rheum. 2004;50:2580-9.
36.  Seror R, Sordet C, Guillevin L, et al. Tolerance and efficacy of rituximab and 
changes in serum B cell biomarkers in patients with systemic complications 
of primary Sjogren’s syndrome. Ann Rheum Dis. 2007;66:351-7.
37.  Tanaka Y, Yamamoto K, Takeuchi T, et al. A multicenter phase I/II trial of 
rituximab for refractory systemic lupus erythematosus. Mod Rheumatol. 
2007;17:191-7.
38.  Maeda T, Yamada Y, Tawara M, et al. Successful treatment with a chimeric 
anti-CD20 monoclonal antibody (IDEC-C2B8, rituximab) for a patient with 
relapsed mantle cell lymphoma who developed a human anti-chimeric 
antibody. Int J Hematol. 2001;74:70-5.
39.  Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple 
intravenous infusions of anti-tumor necrosis factor alpha monoclonal 
antibody combined with low-dose weekly methotrexate in rheumatoid 
arthritis. Arthritis Rheum. 1998;41:1552-63.
Peters, et al. Rituximab in minimal change nephropathy and focal segmental glomerulosclerosis.
